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Abstract
Background: Extravasation injuries are caused by unintended leakages of fluids or medicines from intravenous lines
but there is no consensus on the best treatment approaches, particularly in infants and young children.
Methods: This paper presents a more succinct account of a study of treatments for extravasation injuries in infants
and children which has also been reported in full as an NIHR HTA report. A systematic scoping review and survey
of UK NHS practice were undertaken. Twelve databases - including MEDLINE and EMBASE - were searched for
relevant studies in February 2017. Studies of children with extravasation injuries receiving any treatment for
extravasation injury were eligible, providing they reported one of the following outcomes: wound healing time,
infection, pain, scarring, functional impairment, and requirement for surgery. Studies were screened in duplicate.
Data were extracted by one researcher and checked by another. Studies were summarised narratively. An online
questionnaire was distributed to NHS staff at neonatal units, paediatric intensive care units and principal oncology/
haematology units.
Results: The evidence identified in the scoping review was mostly comprised of small, retrospective, uncontrolled
group studies or case reports. The studies covered a wide range of interventions including conservative management
approaches, saline flush-out techniques (with or without prior hyaluronidase), hyaluronidase without flush-out, artificial
skin treatments, debridement and plastic surgery. Few studies graded injury severity and the results sections and
outcomes reported in most studies were limited. There was heterogeneity across study populations in many factors.
The survey yielded 63 responses from hospital units across the UK. Results indicated that although most units had
written documentation for treating extravasation injuries, only one-third of documents included a system for grading
injury severity. The most frequently used interventions were elevation of the affected area and analgesics. Saline wash-
out treatments, either with or without hyaluronidase, were regularly used in about half of all neonatal units. Most
responders thought a randomised controlled trial might be a viable future research design.
Conclusions: There is some uncertainty about which are most the promising treatments for extravasation injuries in
infants and young children. Saline flush-out techniques and conservative management approaches are commonly
used and may be suitable for evaluation in trials. Although conventional randomised trials may be difficult to perform a
randomised registry trial may be an appropriate alternative design.
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Background
Intravenous (IV) access for the provision of medication and
nutrition is a common, and in many cases essential, proced-
ure when treating children and infants in hospital. Although
adverse outcomes resulting from IV access are rare, the pro-
cedure is not without risk. Extravasation injuries are caused
by unintended leakages of fluids or medicines from IV lines
in which a fluid deviates from its planned pathway - the vein
- into surrounding tissue. These injuries can cause pain, in-
flammation, tendon or nerve damage and predispose to
local and invasive infection, ulceration and tissue necrosis.
Initial treatments aim to reduce pain and prevent or minim-
ise local tissue necrosis and associated functional and cos-
metic impairment. Injuries which result in tissue necrosis
seem to be more prevalent in neonates and younger infants.
This is likely to be due to their immature skin, fragile veins,
lack of subcutaneous tissue, limited ability to report pain,
likelihood of needing longer periods of intravenous treat-
ment, limited number of venous access sites, the small-bore
of catheters and the small drug volume. This paper presents
a more succinct account of a study of treatments for ex-
travasation injuries in infants and children which has also
been reported in full as an NIHR HTA report. [1]
There is some uncertainty about the incidence of
extravasation injuries in children. Across different oncology
populations (including adults) reports range between 0.01
and 7% for chemotherapy extravasations. [2] A study of
1409 neonates reported a severe injury rate of 2.4% with
total parenteral nutrition solution being involved in most
cases. [3] Extravasation injuries have been classified into four
stages of increasing severity based on assessment of pain,
erythema, swelling, blanching, capillary refill, and pulse vol-
ume. [4] Although these Millam guidelines may generally be
useful in predicting injury prognosis, and in determining the
best treatment results, they appear to have a more limited
value in paediatric populations. [5, 6]
Treatment strategies are normally driven by the type
and extent of the injury, the type of infusate and by the
time-interval between injury identification and subse-
quent intervention. Although treatment options are
many and varied there is no consensus on the best ap-
proach to management, with guidelines sometimes offer-
ing conflicting recommendations. [7–9] This is likely a
result of the limited research evidence available, particu-
larly in newborns and infants. Consequently, it is unsur-
prising that policies seem to be largely based on
historical practice within hospitals or expert opinion, ra-
ther than on published guidelines. [10] This study aimed
to begin the process of resolving the uncertainty sur-
rounding which treatments may be best for treating ex-
travasation injuries in infants and young children. This
was done by undertaking both a systematic scoping re-




A scoping review was undertaken to determine which treat-
ments appear likely to be the most promising for future
study. The review was based on the framework proposed in
key scoping review methodology papers. [11–13] In Febru-
ary 2017, the following databases were searched to identify
published and unpublished studies in any language: MED-
LINE, British Nursing Index (BNI), Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), Cochrane Database of
Systematic Reviews (CDSR), Cumulative Index to Nursing
& Allied Health (CINAHL Plus), Database of Abstracts of
Reviews of Effects (DARE), EMBASE, EMCARE, Proquest
Dissertations & Theses: UK & Ireland, Conference Proceed-
ings Citation Index: Science, Health Technology Assessment
(HTA) Database, Maternity and Infant Care (MIC), PubMed
and Science Citation Index. We also searched three clinical
trial registries for ongoing studies: ClinicalTrials.gov, EU
Clinical Trials Register, and the WHO International Clinical
Trials Registry Platform portal. An example search strategy
(for MEDLINE) is presented in Additional file 1.
Eligible studies were of children (aged < 18 years) with an
extravasation injury of the skin, subcutaneous tissue or
muscle tissue, associated with central or peripheral intraven-
ous access. Any interventions or comparators were eligible.
The outcomes of interest were: wound healing time, scar-
ring, infection, pain, contractures, functional impairment,
disfigurement, requirement for surgery, mortality, and ana-
phylactic reactions to extravasation treatments. Any study
design was eligible. We included any identified reviews
(which had a focus on treatments) and guidelines to provide
the basis for an overview of the evidence for extravasation
treatments more broadly, i.e. studies of adults, since it was
possible that some of this evidence might have been more
methodologically robust than the studies in children.
Two reviewers independently assessed titles and abstracts
for eligibility. The full texts of potentially relevant titles and
abstracts were sought and assessed independently by two re-
viewers, with disagreements resolved through discussion or
via a third reviewer. Piloted data extraction forms for com-
parative studies, non-comparative studies and case reports
were used to record details of study methods, population
characteristics (such as age, type of infusate, and injury se-
verity), interventions (type, number and frequency of treat-
ments), comparators, outcome measures, and results. Any
recommendations for future research which were relevant
to the aims of this scoping review were also extracted. Data
were extracted by one researcher and checked by another.
Studies were synthesised, and summarised narratively.
Survey
An NHS survey was undertaken to inform on which
treatment approaches are currently used and to elicit
opinions regarding which interventions are most worthy
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of future research. A systematic approach was used to
develop the questionnaire content, informed mainly by
initial findings from the scoping review and peer-to-peer
consultation of clinicians. The questionnaire was de-
signed and distributed using Qualtrics software. It was
piloted among colleagues at neonatal and paediatric
units in York, Bradford and Leeds and distributed to
NHS staff at neonatal units, paediatric intensive care
units (PICUs) and principal oncology/haematology units




From the database searches 3830 records were identi-
fied for title and abstract screening, from which 289
records were selected as being of interest. After
screening full papers we included 26 group studies,
six guidelines, three reviews and 106 case report stud-
ies (Fig. 1). Case report details and references are
available in Additional file 3.
Of the 26 included group studies only two were com-
parative (neither were randomised studies) and both had
limitations. [9, 14] One was an old quasi-randomised
study of treatments which are now not commonly used
(silver sulfadiazine cream and povidone-iodine oint-
ment). [14] It included 34 patients with quite severe
wounds where the extravasation injuries may not have
been identified for quite some time. The other study was
not primarily designed to evaluate treatment effective-
ness. Although it did endeavour to determine if hyal-
uronidase treatment resulted in less harm than no
hyaluronidase treatment, the before-and-after design,
lack of population details, and lack of details on inter-
ventions given to the no hyaluronidase group, mean the
study’s ‘harm score’ result should not be regarded as a
reliable estimate of hyaluronidase effectiveness. [9] Full
details and results of both studies are in the
Additional file 4.
Although many types of extravasation injury treatments
have been studied in the 24 non-comparative studies
which were included, the limitations inherent in these
studies make it very difficult to compare results across
treatments; details and results of the non-comparative
studies are presented in Additional file 4. Some results are
likely to have been subject to chance effects or biases be-
cause most studies were very small and were retrospective
in design: 17 of the 24 studies had sample sizes of less
than 20, and only three studies were reported as having a
prospective design. Furthermore, there was considerable
clinical heterogeneity across study populations in factors
such as age, types of infusate, injury severity, location of
injury, and time between injury and treatment. Differences
in results across studies might be a reflection of variation
in one or more of these parameters, rather than differ-
ences in treatment effectiveness. Although data on injury
severity grading could have helped with interpreting the
importance of these issues, few studies reported such data
(only 3 of the group studies). The results sections for most
studies were very brief and reported limited results data.
Moreover, the reported outcomes often related to
short-term time points. No studies reported pain as an
outcome and few studies quantified outcomes – e.g. using
measures of scarring, such as scar scores. Only one study
reported on whether or not interventions resulted in ad-
verse effects. [15]
Some of the better evidence (in terms of study size
and use of a prospective design) related to studies of sa-
line flush-out techniques, which appear to be quite
promising treatments. The effect of prior infiltration
with hyaluronidase before wash-out is unclear though.
Neonates were the most frequently studied popula-
tion, being evaluated in around half the non-
comparative studies. Sung & Lee suggested that the
use of flush-out methods in neonates may be too in-
vasive to perform and therefore proposed a middle
ground between conservative management and flush-
out: puncture points and hydrocolloid dressing. [16]
However, although two of the 12 (mostly) pre-term
neonates in this South Korean study presented with
necrotic lesions, nine eventually progressed to full
thickness open wounds. Besides, two group studies
have reported results for flush-out treatments used in
neonates. [3, 17] One of them was prospectively per-
formed in a UK neonatal unit, but was published only
as a letter and so only described the population as
‘neonates’ along with very basic result details. [17]
The other study was conducted in a Greek neonatal
intensive care unit in mostly very pre-term or late
pre-term neonates with quite severe (stage III or IV)
extravasation injuries. [3] This study reported impres-
sive results with 21 of 34 neonates showing no signs
of soft tissue damage 24 h after treatment, and only
minor findings - blistering and epidermolysis - still
present in seven neonates in the following few days.
These results might therefore suggest that flush-out
may be more worthy of further study than the middle
ground of puncture (without flush-out) and dressing.
However, this is merely a suggestion, as although
both the studies were of parenteral nutrition extrava-
sations in neonates they differed in an important way:
in the Greek study the neonates were treated within
10–30 min of injury compared with between 1 and
10 h in the South Korean study.
All three of the identified reviews concurred that al-
though immediate treatment is needed for the best
outcomes, there is no consensus regarding which treat-
ments constitute best practice. [7, 18, 19] They all
Corbett et al. BMC Pediatrics            (2019) 19:6 Page 3 of 7
mentioned saline washout with or without hyaluronidase
as a frequently studied treatment but no review could
make conclusive statements on its effectiveness com-
pared to other treatments due to the limited quality of
evidence. Seven published guidelines were identified. [2,
8, 20–24] Only one focussed specifically on a paediatric
population. [22] Their recommendations were often
conflicting on treatments, including saline washout, [2,
23] specific antidotes [2, 22] and conservative manage-
ment. For example, the saline flush-out treatment, as
originally proposed by Gault [25] has been described as
very effective and to be recommended, [7] as having
achieved good results, [23] as potentially effective but
lacking in evidence [8] and as not to be recommended
as routine management. [2] They did report similar find-
ings on hyaluronidase (as being effective) and corticoste-
roids (as being ineffective).
Survey
Sixty-three questionnaires were received from 56 differ-
ent hospitals; 71% were from neonatal units, 21% were
from principal oncology/haematology units and 8% were
from PICUs. Forty-eight (76%) questionnaires were re-
ceived from units in England, six (10%) from Scotland,
five (8%) from Northern Ireland and two (3%) from
Wales; two (3%) responses were received from units in
North America. Most responders were either consultant
neonatologists (48%), nursing staff (16%) or consultant
paediatricians (13%). Of 57 responding units, 82% said
they had a written protocol or guideline for treating ex-
travasation injuries, although a staging system for grad-
ing injury severity was included in only around a third
of protocols or guidelines. Almost all responders indi-
cated that peripheral lines were the access site most as-
sociated with extravasation injuries. In neonatal units
Fig. 1 Flow chart showing the number of studies identified and eligible for scoping review inclusion
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parenteral nutrition was the cause of the largest propor-
tion of extravasation injuries. In principal oncology/
haematology units the largest proportion of injuries was
due to vesicant chemotherapies.
The most frequently used intervention approaches
were elevation of the affected area and analgesics (see
Additional file 5). In most units warm or cold com-
presses were rarely or never used. In neonatal units
there was notable variation regarding the use of occlu-
sive dressings, ranging from always being used (8% of re-
sponses) to never being used (31%). Variation in the use
of saline flush-out, either with or without hyaluronidase,
was also evident; these interventions seem to be either
usually or sometimes used in around half of neonatal
units, though never used in around a third of units. Re-
sults for principal oncology/haematology units and
PICUs were broadly similar to the neonatal unit results.
When asked about a future research study, 65% of the
57 responders thought a randomised controlled trial
(RCT) might be viable, 21% did not think an RCT was
viable and 14% did not know. However, the results var-
ied by setting: the proportion thinking an RCT was vi-
able was 83% of the 40 neonatal unit responses, 33% of
the 12 principal oncology/haematology unit responses
and 0% of PICUs. Almost all the responders who
thought a RCT was viable mentioned one or more of
the following types of treatment when asked which
treatments they would most like to see studied: saline
irrigation/wash-out, hyaluronidase and conservative
management. Of those who thought an RCT was not
viable various reasons were provided including the
presence of too many variables which could affect
outcomes, timeliness of treatment when using ran-
domisation, low numbers of patients, and unwilling-
ness to deviate from current practice. Tables of
survey results are presented in the Additional file 5.
Discussion
Our systematic scoping review identified studies which,
together, covered a wide range of treatments for extrava-
sation injuries. However, in considering the study
methods and designs used, small sample sizes, and the
variation across population and intervention characteris-
tics, the quality of evidence overall was very low. Conse-
quently, there is uncertainty about which treatments are
most promising. Notwithstanding the evidence limita-
tions, the results of studies of flush-out techniques sug-
gested that these treatments may be worthy of further
research. This finding was echoed in the NHS survey re-
sults, with flush-out techniques, hyaluronidase and con-
servative management approaches frequently suggested
as being treatments where further study would seem
most worthwhile. Our survey results were similar to
those from previous surveys - conducted in the USA
[26] Australia and New Zealand [27] and Britain [28] -
in demonstrating a lack of consensus on the best course
of treatment for extravasation injuries. The main limita-
tion of our study related to the scoping review evidence
identified - most studies were very limited in helping to
evaluate relative treatment efficacy.
In planning a future comparative study of extravasa-
tion injury treatments, population heterogeneity, low in-
jury rates and sporadic incidence are key issues. In light
of this, the most viable population for any randomised
trial may be preterm neonates receiving IV parenteral
nutrition at a peripheral site, although this treatment ap-
proach is quite rare, and is not usually recommended. A
paucity of standardised relevant outcome measures used
in previous studies in neonates is also a concern. Out-
come measures used in a future study would ideally
need to be clinically practicable but also be able to dem-
onstrate adequate reliability and validity. Although a
conventional parallel-group randomised controlled trial
might seem the ideal design to use in a future study, it is
likely to be difficult to overcome the following issues:
avoiding treatment delays, selection bias and the recruit-
ment of adequate numbers of participants. Since ex-
travasation injuries require urgent treatment any delay
due to recruitment and randomisation processes might
be difficult to justify. A frequently used method of ran-
domisation is sequentially numbered, opaque, sealed en-
velopes containing randomly generated treatment
allocations. Adoption of this method might minimise
treatment delays, but this approach has been demon-
strated to be prone to investigator selection bias. [29]
Extravasation injuries are quite rare events which are
also subject to variation, particularly in terms of patients
(ages, comorbidities), causes (infusates), injury sites and
severities, and the speed at which injuries are detected
and treated. Consequently, careful consideration would
be needed when devising trial eligibility criteria to enable
the recruitment of both a sufficiently homogeneous sam-
ple of participants and a sample which would be large
enough to minimise the impact of chance differences
across treatment groups in any of these factors. Failure
to do so would increase the risk of false-positive trial re-
sults; small trials are more prone to yielding chance re-
sults than larger trials.
Alternatives to conventional RCT designs should
therefore be considered. Although a prospective, obser-
vational database study would maximise the number of
patients recruited, and eliminate concerns about treat-
ment delays, its results would inherently be subject to
uncertainty due to the likelihood of selection bias.
Nevertheless, a randomised registry trial design could be
used which incorporates many of the best aspects of
both conventional RCTs and observational database
studies. [30] Issues (highlighted by our survey results)
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which should be considered in any randomised registry
trial of neonates include the lack of a protocol or guide-
line for treating extravasation injuries in some units, and
the absence of the use of a system for grading injury se-
verity in many units which do have access to a protocol
or guideline. There may also be variation in the injury
severity grading systems used; it has been argued that
the Millam guidelines are not appropriate in paediatric
populations [5, 6] with alternatives proposing the inclu-
sion of assessment of the number of joints involved [5]
or the percentage of the limb affected. [6]
Conclusions
Studies of treatments for extravasation injuries in babies
and children are mostly very small, lack comparator
groups, and are varied in terms of patient, intervention
and outcome characteristics. Consequently, there is un-
certainty about which treatments are most promising.
However, the results of studies of flush-out techniques
suggest that these treatments may be worthy of further
research. NHS survey results echoed this finding with
hyaluronidase and conservative management frequently
also suggested as being treatments where further study
would be most worthwhile. Nevertheless, some of the
practicalities involved in undertaking a conventional ran-
domised controlled trial - such as recruiting adequate
numbers, avoiding treatment delays and selection bias -
could be difficult to overcome. An alternative design is
the randomised registry trial, which incorporates many
of the best aspects of both conventional RCTs and ob-
servational database studies.
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